Novavax vaccine recommended for approval for EU teenagers

A positive recommendation from the EU committee CHMP concerning the use of the Novavax vaccine in teenagers has turned Novavax’s stock fortunes upside down after months of losses.

Shares in US-based vaccine producer Novovax increased in value by 13.9% on Thursday in US trading after the Committee for Medicinal Products for Human Use, the CHMP, recommended the vaccine be used in children aged 12-17.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs